Vanda Pharmaceuticals Inc Market Cap ($221.66 Million)
Market Cap & Net Worth: Vanda Pharmaceuticals Inc (VNDA)
Vanda Pharmaceuticals Inc market cap. Vanda Pharmaceuticals Inc (NASDAQ:VNDA) has a market capitalization of $221.66 Million ($221.66 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15961 globally and #3815 in its home market, demonstrating a -4.82% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vanda Pharmaceuticals Inc's stock price $3.75 by its total outstanding shares 59108030 (59.11 Million). Also see cash flow conversion of Vanda Pharmaceuticals Inc for how efficiently the company converts equity into cash flow.
Vanda Pharmaceuticals Inc Market Cap History (2015–2026)
Vanda Pharmaceuticals Inc market cap history from 2015 to 2026. Data shows change from $550.30 Million to $221.66 Million (-9.01% CAGR). Check VNDA stock price and chart for real-time trading data and today's change.
Index Memberships
Vanda Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.01% | #430 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1568 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.01% | #218 of 263 |
Weight: Vanda Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Vanda Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vanda Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Vanda Pharmaceuticals Inc growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.41x
Vanda Pharmaceuticals Inc's market cap is 2.41 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $942.77 Million | $146.02 Million | -$18.01 Million | 6.46x | N/A |
| 2017 | $898.44 Million | $165.08 Million | -$15.57 Million | 5.44x | N/A |
| 2018 | $1.54 Billion | $193.12 Million | $25.21 Million | 8.00x | 61.27x |
| 2019 | $969.96 Million | $227.19 Million | $115.55 Million | 4.27x | 8.39x |
| 2020 | $776.68 Million | $248.17 Million | $23.34 Million | 3.13x | 33.28x |
| 2021 | $927.40 Million | $268.68 Million | $33.15 Million | 3.45x | 27.97x |
| 2022 | $436.81 Million | $254.38 Million | $6.28 Million | 1.72x | 69.61x |
| 2023 | $249.44 Million | $192.64 Million | $2.51 Million | 1.29x | 99.42x |
| 2024 | $283.13 Million | $198.77 Million | -$18.90 Million | 1.42x | N/A |
| 2025 | $521.33 Million | $216.10 Million | -$220.47 Million | 2.41x | N/A |
Competitor Companies of VNDA by Market Capitalization
Companies near Vanda Pharmaceuticals Inc in the global market cap rankings as of November 4, 2026. Also see VNDA total assets for a full breakdown of the balance sheet.
Key companies related to Vanda Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Vanda Pharmaceuticals Inc (2015–2026)
Market capitalization of Vanda Pharmaceuticals Inc from 2015 to today. Between 2015 and today, Vanda Pharmaceuticals Inc's market cap moved from $550.30 Million to $ 221.66 Million, with a yearly change of -9.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $221.66 Million | -57.48% |
| 2025 | $521.33 Million | +84.13% |
| 2024 | $283.13 Million | +13.51% |
| 2023 | $249.44 Million | -42.90% |
| 2022 | $436.81 Million | -52.90% |
| 2021 | $927.40 Million | +19.41% |
| 2020 | $776.68 Million | -19.93% |
| 2019 | $969.96 Million | -37.20% |
| 2018 | $1.54 Billion | +71.91% |
| 2017 | $898.44 Million | -4.70% |
| 2016 | $942.77 Million | +71.32% |
| 2015 | $550.30 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Vanda Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $221.66 Million USD |
| MoneyControl | $221.66 Million USD |
| MarketWatch | $221.66 Million USD |
| marketcap.company | $221.66 Million USD |
| Reuters | $221.66 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nightt… Read more